Actuate Therapeutics (ACTU) Competitors

$2.38 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.40 +0.02 (+1.05%)

As of 05/22/2026 06:40 PM Eastern

ACTU vs. EDIT, AVXL, ACIU, ALXO, and CHRS

Should you buy Actuate Therapeutics stock or one of its competitors? MarketBeat compares Actuate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actuate Therapeutics include Editas Medicine (EDIT), Anavex Life Sciences (AVXL), AC Immune (ACIU), ALX Oncology (ALXO), and Coherus Oncology (CHRS). These companies are all part of the "pharmaceutical products" industry.

How does Actuate Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

71.9% of Editas Medicine shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Actuate Therapeutics has lower revenue, but higher earnings than Editas Medicine. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.67	-$160.06M	-$1.23	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Editas Medicine presently has a consensus price target of $5.40, suggesting a potential upside of 95.65%. Actuate Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 635.29%. Given Actuate Therapeutics' higher possible upside, analysts plainly believe Actuate Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Actuate Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Actuate Therapeutics' return on equity of -430.93% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Actuate Therapeutics	N/A	-430.93%	-180.86%

In the previous week, Actuate Therapeutics had 17 more articles in the media than Editas Medicine. MarketBeat recorded 18 mentions for Actuate Therapeutics and 1 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.00 beat Actuate Therapeutics' score of -0.26 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Editas Medicine has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Summary

Editas Medicine beats Actuate Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Anavex Life Sciences' return on equity of -38.76% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Actuate Therapeutics	N/A	-430.93%	-180.86%

In the previous week, Actuate Therapeutics had 16 more articles in the media than Anavex Life Sciences. MarketBeat recorded 18 mentions for Actuate Therapeutics and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.96 beat Actuate Therapeutics' score of -0.26 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences currently has a consensus target price of $21.33, suggesting a potential upside of 693.06%. Actuate Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 635.29%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Actuate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

31.6% of Anavex Life Sciences shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anavex Life Sciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Summary

Anavex Life Sciences beats Actuate Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to AC Immune?

Actuate Therapeutics (NASDAQ:ACTU) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Actuate Therapeutics currently has a consensus price target of $17.50, suggesting a potential upside of 635.29%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 165.02%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Actuate Therapeutics is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

51.4% of AC Immune shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Actuate Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

Actuate Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
AC Immune	-1,788.02%	-125.26%	-40.85%

In the previous week, Actuate Therapeutics had 15 more articles in the media than AC Immune. MarketBeat recorded 18 mentions for Actuate Therapeutics and 3 mentions for AC Immune. AC Immune's average media sentiment score of 0.92 beat Actuate Therapeutics' score of -0.26 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actuate Therapeutics has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
AC Immune	$4.31M	66.82	-$85.03M	-$0.82	N/A

Summary

Actuate Therapeutics and AC Immune tied by winning 7 of the 14 factors compared between the two stocks.

How does Actuate Therapeutics compare to ALX Oncology?

Actuate Therapeutics (NASDAQ:ACTU) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

98.0% of ALX Oncology shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Actuate Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

In the previous week, Actuate Therapeutics had 18 more articles in the media than ALX Oncology. MarketBeat recorded 18 mentions for Actuate Therapeutics and 0 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.00 beat Actuate Therapeutics' score of -0.26 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
ALX Oncology	Neutral

Actuate Therapeutics currently has a consensus target price of $17.50, indicating a potential upside of 635.29%. ALX Oncology has a consensus target price of $4.60, indicating a potential upside of 132.32%. Given Actuate Therapeutics' higher probable upside, equities analysts clearly believe Actuate Therapeutics is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

ALX Oncology's return on equity of -124.06% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
ALX Oncology	N/A	-124.06%	-85.57%

Summary

ALX Oncology beats Actuate Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Actuate Therapeutics compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, Actuate Therapeutics had 18 more articles in the media than Coherus Oncology. MarketBeat recorded 18 mentions for Actuate Therapeutics and 0 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.00 beat Actuate Therapeutics' score of -0.26 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Coherus Oncology	Neutral
Actuate Therapeutics	Neutral

Coherus Oncology has a net margin of 397.30% compared to Actuate Therapeutics' net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Actuate Therapeutics	N/A	-430.93%	-180.86%

72.8% of Coherus Oncology shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Coherus Oncology has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Coherus Oncology presently has a consensus target price of $8.67, indicating a potential upside of 438.30%. Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 635.29%. Given Actuate Therapeutics' higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Coherus Oncology has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.89	$168.02M	$1.67	0.96
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Summary

Coherus Oncology beats Actuate Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$56.94M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-2.45	18.74	21.22	25.65
Price / Sales	N/A	323.98	553.92	86.28
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	14.88	7.09	10.37	7.14
Net Income	-$22.23M	$24.45M	$3.57B	$335.98M
7 Day Performance	-0.83%	6.38%	6.40%	4.15%
1 Month Performance	-19.87%	2.43%	3.52%	2.54%
1 Year Performance	-76.96%	62.98%	34.02%	35.05%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	2.0131 of 5 stars	$2.38 flat	$17.50 +635.3%	-77.0%	$56.94M	N/A	N/A	10	Analyst Downgrade Gap Up
EDIT Editas Medicine	2.8508 of 5 stars	$2.89 -1.5%	$5.40 +87.2%	+78.1%	$282.47M	$40.52M	N/A	230
AVXL Anavex Life Sciences	2.0546 of 5 stars	$3.06 -0.2%	$21.33 +598.3%	-64.3%	$282.18M	N/A	N/A	40	Upcoming Earnings
ACIU AC Immune	2.6417 of 5 stars	$2.77 flat	$7.50 +170.8%	+67.5%	$281.90M	$4.31M	N/A	140
ALXO ALX Oncology	2.7162 of 5 stars	$2.08 +2.2%	$4.60 +121.7%	+327.0%	$279.21M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. EDIT, AVXL, ACIU, ALXO, and CHRS

How does Actuate Therapeutics compare to Editas Medicine?

Summary

How does Actuate Therapeutics compare to Anavex Life Sciences?

Summary

How does Actuate Therapeutics compare to AC Immune?

Summary

How does Actuate Therapeutics compare to ALX Oncology?

Summary

How does Actuate Therapeutics compare to Coherus Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. EDIT, AVXL, ACIU, ALXO, and CHRS

How does Actuate Therapeutics compare to Editas Medicine?

Do insiders & institutionals have more ownership in EDIT or ACTU?

Which has stronger earnings & valuation, EDIT or ACTU?

Do analysts prefer EDIT or ACTU?

Is EDIT or ACTU more profitable?

Does the media refer more to EDIT or ACTU?

Which has more volatility & risk, EDIT or ACTU?

Summary

How does Actuate Therapeutics compare to Anavex Life Sciences?

Is AVXL or ACTU more profitable?

Does the media refer more to AVXL or ACTU?

Do analysts prefer AVXL or ACTU?

Which has better earnings and valuation, AVXL or ACTU?

Do institutionals and insiders have more ownership in AVXL or ACTU?

Which has more volatility and risk, AVXL or ACTU?

Summary

How does Actuate Therapeutics compare to AC Immune?

Do analysts recommend ACTU or ACIU?

Do insiders and institutionals hold more shares of ACTU or ACIU?

Which has more volatility & risk, ACTU or ACIU?

Is ACTU or ACIU more profitable?

Does the media favor ACTU or ACIU?

Which has better valuation and earnings, ACTU or ACIU?

Summary

How does Actuate Therapeutics compare to ALX Oncology?

Which has higher valuation & earnings, ACTU or ALXO?

Do insiders & institutionals believe in ACTU or ALXO?

Which has more volatility & risk, ACTU or ALXO?

Does the media prefer ACTU or ALXO?

Do analysts rate ACTU or ALXO?

Is ACTU or ALXO more profitable?

Summary

How does Actuate Therapeutics compare to Coherus Oncology?

Does the media favor CHRS or ACTU?

Is CHRS or ACTU more profitable?

Do institutionals & insiders believe in CHRS or ACTU?

Which has more risk and volatility, CHRS or ACTU?

Do analysts recommend CHRS or ACTU?

Which has better valuation & earnings, CHRS or ACTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools